Treats generalized pustular psoriasis (GPP). Sold as Spevigo. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Spesolimab-Sbzo (sold as Spevigo), first approved Sep 1, 2022, with 2 new uses approved and 0 published complete response letters.
| Spevigo | Part D | $18.0M | +268% | 138 |
| Spevigo | Part B | $4.0M | -13% | 36 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Sep 1, 2022 | SpevigoBLA 761244 · New molecular entity | Boehringer Ingelheim Pharmaceuticals Inc | 4 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
